Mahtta, Dhruv
Lee, Michelle T.
Ramsey, David J.
Akeroyd, Julia M.
Krittanawong, Chayakrit
Khan, Safi U.
Sinh, Preetika
Alam, Mahboob
Garratt, Kirk N.
Schofield, Richard S.
Ballantyne, Christie M.
Petersen, Laura A.
Virani, Salim S. http://orcid.org/0000-0001-9541-6954
Funding for this research was provided by:
U.S. Department of Veterans Affairs (IIR 16–072)
American Heart Association (14BGIA20460366)
ADA Foundation (1-14- CE-44)
Article History
Accepted: 8 December 2020
First Online: 5 January 2021
Compliance with Ethical Standards
:
: <i>Dhruv Mahtta, Michelle T. Lee, David J. Ramsey, Chayakrit Krittanawong, Julia M. Akeroyd, Safi U. Khan, Preetika Sinh, Mahboob Alam, Kirk N. Garratt, Richard S. Schofield, Laura A. Petersen:</i> None.<i>Christie M. Ballantyne:</i> Grant/Research Support—all significant (all paid to institution, not individual): Akcea, Amgen, Esperion, Novartis, Regeneron, Sanofi-Synthelabo, NIH, AHA, ADA.Consultant—Abbott Diagnostics, Akcea, Amarin, Amgen, Arrowhead, Astra Zeneca, Corvidia, Denka Seiken, Esperion, Intercept, Matinas BioPharma Inc., Merck, Novartis, Regeneron, Sanofi-Synthelabo.<i>Salim S. Virani:</i> Honorarium, American College of Cardiology (Associate Editor for Innovations, ExternalRef removed); Steering Committee, Patient and Provider Assessment of Lipid Management (PALM registry) at the Duke Clinical Research Institute (no financial remuneration).
: The institutional review boards at Baylor College of Medicine and the Michael E. DeBakey VA Medical Center approved the study protocol. An approval was also obtained for the informed consent waiver.